Category Archives: Public Policy

Latest From Public Policy

Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2)

Meeting

The Trans Pacific Partnership (TPP) negotiation does not yet include a section on data protection (typically included in the Pharmaceutical Chapter of Free Trade Agreements).  Organizations against the inclusion of data protection in the TPP cite as evidence an Oxfam International study titled “All Costs, No Benefits: How TRIPS-plus intellectual property rules in the US-Jordan FTA affect access to medicines.” The Oxfam paper concludes that “medicine prices have increased drastically, and TRIPS-plus rules were partly Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Non-Communicable Diseases and IP?

Flags

On September 19 and 20, the United Nations meets to potentially adopt a declaration on non-communicable diseases similar to the 2001 Declaration of Commitment on HIV/AIDS.  The diseases of particular focus include cardiovascular disease, diabetes, cancer, and respiratory disease.  Similar to previous UN initiatives around HIV/AIDS, the meeting will focus on developmental, social and economic impacts and other challenges, particularly for developing countries. UN background documents mention IP and it is possible that UN negotiations may Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Tech Transfer Summit North America

Tech Transfer Summit

The National Institutes of Health, BIO, and others are sponsoring the Tech Transfer Summit North America at NIH on 3-4 October 2011. Programming includes Translational Medicine & Funding Innovation, Successful Implementation of Biotech Innovation Strategies Worldwide, and Building Better Academia-Industry Collaborations: How will Big Pharma fill its early-stage Pipeline in 5 years’ time, among other topics. BIO’s President and CEO James C. Greenwood will give one keynote speach on the “Barriers to Innovation in biotechnology, and Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

State Legislator Profile: Washington State Rep. John McCoy

Washington State Rep. John McCoy (D-Tulalip)

If you ask most people to name a few things about the state of Washington, the word technology is likely to wind up somewhere in the mix. However, the birthplace of Microsoft and Amazon.com is also a biotech heavyweight. Washington contains one of the world’s largest life sciences clusters and is home to dozens of research institutes and some of the nation’s leading public research universities. The biotech industry in Washington employs tens of thousands Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , ,

Biotechnology Patenting in Europe Event

2390666040_2e6b0a9a78_m

BIO hosted a Biotechnology Patenting in Europe event last week here at BIO’s offices where attorneys from Carpmaels and Ransford addressed various issues of interest to U.S. biotechnology companies. Huw Halleybone discussed the relative challenges of patent harmonization in Europe quoting some reports that indicate that the cost of a European patent is 10 times the amount of the United States.  Most of this cost is mainly due to language translation requirements and renewal fees.  Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,